NCT01601002View on ClinicalTrials.gov

LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
Major Depressive Disorder
Interventions
DRUG

Mirtazapine

Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label

Trial Locations (1)

N6A 5W9

London Health Sciences Centre, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT01601002 - LEPR Polymorphism Weight Gain by Mirtazapine in Late Life Depression | Biotech Hunter | Biotech Hunter